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Introduction
Confronted with the universal critical organ shortage,
many transplant centers have started the use of donation
after cardio-circulatory death (DCD) as an alternative
donor source. Results of kidney transplantation (KT)
from DCD over the past 30 years showed comparable
results with those from donation after brain death (DBD)
[1–7]. These results of DCD-KT have led Belgian trans-
plant centers to revisit this option and urged the Belgian
National Council of Physicians on organ procurement
from DCD [8]. The first DCD-KT was performed in Bel-
gium in 2000, and up to now all seven Belgian transplant
centers have active DCD-KT programs [9,10]. In 2009,
there were 60 DCD procurements [21.7% of the deceased
donor (DD) pool] and 74 DCD-KT (17.3% of the DD
kidney pool) in comparison with 9 DCD procurements
(3.8%) and 14 DCD-KT (3.9%) in 2005. A preliminary
report over 44 DCD-KT in Belgium during the 2003–
2005 period showed a delayed graft function (DGF) rate
of 20.5% and a primary nonfunction (PNF) rate of 9.1%.
DCD kidneys preserved by machine perfusion had a sig-
nificant lower rate of DGF than cold-stored kidneys (25%
vs. 42%) and the risk of graft loss of 3% [8].
The University Hospital of Lie`ge initiated a program of
controlled DCD-KT in 2005 [11]. This study was aimed
at evaluating results of DCD-KT at our institute with
regard to short- and mid-term graft function, graft and
patient survival, rejection and surgical complications. The
influence of DGF on graft function and survival as well as
the potential DGF risk factors were also analyzed as
secondary end-points.
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Summary
The aim of this study was to determine results of kidney transplantation (KT)
from controlled donation after cardio-circulatory death (DCD). Primary end-
points were graft and patient survival, and post-transplant complications. The
influence of delayed graft function (DGF) on graft survival and DGF risk fac-
tors were analyzed as secondary end-points. This is a retrospective mono-center
review of a consecutive series of 59 DCD-KT performed between 2005 and
2010. Overall graft survival was 96.6%, 94.6%, and 90.7% at 3 months, 1 and
3 years, respectively. Main cause of graft loss was patient’s death with a func-
tioning graft. No primary nonfunction grafts. Renal graft function was subopti-
mal at hospital discharge, but nearly normalized at 3 months. DGF was
observed in 45.6% of all DCD-KT. DGF significantly increased postoperative
length of hospitalization, but had no deleterious impact on graft function or
survival. Donor body mass index ‡30 was the only donor factor that was found
to significantly increase the risk of DGF (P < 0.05). Despite a higher rate of
DGF, controlled DCD-KT offers a valuable contribution to the pool of
deceased donor kidney grafts, with comparable mid-term results to those pro-
cured after brain death.
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Patients and methods
This study is a retrospective review of the experience of
the Department of Abdominal Surgery and Transplanta-
tion at the University Hospital of Lie`ge with controlled
DCD-KT from 2005 to 2010. Kidneys procured from
DCD donors were distributed within the Eurotransplant
organization according to the same allocation rules as
DBD kidneys (except Germany and Croatia where organ
procurement and transplantation activity from DCD are
prohibited by Law). The rate of local, national, and inter-
national sharing was 47.5%, 44.1%, and 8.5%, respec-
tively, in this series. The acceptance criteria for DCD
kidneys were as follows: donor age less than 65 years; no
history of renal disease, uncontrolled hypertension, com-
plicated diabetes mellitus, systemic sepsis or malignancy;
warm ischemia time (WIT) less than 45 min (from car-
dio-circulatory arrest to aortic cold perfusion) or less
than 60 min (from withdrawal of life-support to aortic
cold perfusion) [12] and terminal serum creatinine
<20 mg/l. Donor characteristics are presented in Table 1.
Withdrawal of life support occurred in the operating
room. Heparine was injected intravenously prior to with-
drawal of both ventilator and cardiac support in most
DCD donors. Vital signs (blood pressure, heart rate,
respiratory rate, and trans-cutaneous oxygen saturation)
were monitored after discontinuation of treatment until
cardio-circulatory arrest took place. Cardio-circulatory
arrest was defined by femoral mean arterial pressure less
than 30 mmHg without arterial pulse. A 5 min no-touch
period was respected after cardio-circulatory arrest, then
cardio-circulatory death was declared. Rapid laparotomy
with direct aortic cannulation technique was utilized to in
situ perfuse organs. HTK was the most common used
preservation solution (84.7%) and kidneys were cold-
stored in most cases (83.1%). Ten kidney allografts were
preserved by the hypothermic machine perfusion (HMP)
technique in the context of a Eurotransplant randomized
controlled trial about the efficacy of HMP over static cold
storage (SCS) [13]. Mean total WIT was 20.1 ± 7.2 min
(range: 8–39). This time period comprised the withdrawal
phase (from treatment discontinuation to cardio-circula-
tory arrest, mean: 9.4 ± 5.5 min, range: 2–30) and the
acirculatory phase (from cardio-circulatory arrest to initi-
ation of aortic cold perfusion, mean: 10.6 ± 4.8 min,
range: 5–27). Mean cold ischemia time (CIT), defined as
the time interval from aortic cold perfusion until removal
of the kidney graft out of the cold preservation solution
for implantation, was 731.3 ± 267.5 min (range: 207–
1255). Mean vascular anastomosis suture time was
35.1 ± 9.7 min (range: 18–60).
Recipient variables are summarized in Table 2. Mean
recipient age was 54.9 ± 13.5 years (range: 21–76). Recip-
ients older than 65 years received kidneys from older
donors in the context of Eurotransplant Senior Program
[14]. Mean panel reactive antibodies (PRA) at transplant
was 5.2% ± 15.2% (range: 0–75). Mean number of HLA
(human leukocyte antigens) mismatches was 2.8 ± 1.0
(range: 0–4). The frequency of 0, 1, 2, 3, and 4 HLA mis-
matches was 1.7%, 8.5%, 28.8%, 32.2%, and 28.8%,
respectively. Ureteral double J catheter was utilized in half
of the patients (49.2%), largely depending on the sur-
geon’s preference and experience. All recipients received
induction therapy with anti-CD25 monoclonal antibody
(basiliximab) and a standard triple therapy with tacroli-
mus or cyclosporin, mycophenolate mofetil or mycophen-
olic acid and steroids. Anti-infective prophylaxis
comprised sulfamethoxazole/trimethoprim for pneumo-
cystis and urinary tract infection for at least 6–12 months,
valganciclovir for cytomegalovirus (CMV) depending on
donor and recipient CMV serologic status (if D+/R): val-
ganciclovir for 3 months, other cases: acyclovir for herpes
virus for 3 months). Diagnosis of renal allograft rejection
was suggested by an unexplained rise in serum creatinine
level of >0.3 mg/dl or a 25% increase from baseline level
and confirmed by ultrasound-guided per-cutaneous
Table 1. Donor characteristics.
Donor characteristics Mean ± SD or n (%) Range













Donor cause of death








7.1 ± 6.5 0–24*
Terminal serum
creatinine (mg/l)
7.5 ± 3.1 2.3–17.2
24 h diuresis (ml) 2841.6 ± 1312.2 1270–5940
Last hour diuresis prior
to procurement (ml)
144.2 ± 125.3 10–600
*Euthanasia donors did not stay in the ICU.
BMI, body mass index; ICU, intensive care unit.
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biopsy. Renal biopsy was also routinely done for all grafts
at 3 months post-transplant for the purpose of deciding
to withdraw steroids or not. Given the importance of
subclinical rejection as a risk factor for interstitial fibrosis
and tubular atrophy as well as worse glomerular filtration
rate (GFR) and graft survival [15], they were all treated
with bolus of steroids. Donor specific HLA antibody was
checked periodically at the hospital discharge, 3 months
and every year post-transplant, simultaneously at the time
of graft biopsy and after a sensitizing event. Doppler
ultrasound was systemically done at hospital discharge,
3 months and every year post-transplant or at any change
of renal allograft function without clear explanation.
The renal transplant was primary transplant in most
cases (93.2%) with one combined liver–kidney transplan-
tation. There were four re-transplant recipients (6.8%), of
whom, one was immunized with peak PRA of 61% while
the remaining three had no panel reactive antibodies. No
patients developed donor specific antibodies that were
routinely screened by single antigen Luminex technique.
The average number of HLA mismatches was 2.2 ± 1.5
(range: 1–4). Cross-match tests were performed at the
procurement center with the recipient’s historic sera and
repeated again at the transplant center with a recent
serum and these tests must be negative prior to graft
implantation. For primary transplant recipients who were
at low immunological risk, KT was allowed before the
result of cross-match test to shorten the CIT.
Primary endpoints of the study were PNF, DGF, graft
function at the hospital discharge, 3 months, 1, and
3 years post-transplant, graft and patient survival at
3 months, 1, and 3 years post-transplant. PNF was
defined as inadequate renal function after transplantation
that necessitates continuation of dialysis, excluding opera-
tive technical problems. DGF was defined as the require-
ment for haemodialysis during the first week post-
transplant, with subsequent recovery of renal function,
except dialysis treatments to correct hyper-kalemia or vol-
ume overload [16]. Graft function was estimated via
serum creatinine and GFR according to the abbreviated
Modification of Diet in Renal Disease equation [17,18].
Secondary endpoints of the study were the potential risk
factors for DGF, the effect of DGF on graft and patient
survival, duration of post-transplant haemodialysis, length
of patient’s hospital stay, acute rejection rate within the
first 3 months post-transplant and the occurrence of vas-
cular or urological complications. Acute rejection was
diagnosed on the base of the initiation of anti-rejection
treatment or renal biopsy result.
Statistical analysis was as follows: continuous variables
were presented as mean ± standard deviation (SD) and
categorical variables as percentage. Differences between
groups were evaluated by nonparametric Mann–Whitney
U/Wilcoxon Ranked Sum tests for continuous variables
and Fisher’s exact test or Chi square test for categorical
variables. Survival rates were estimated by the Kaplan–
Meier method and compared by the log rank test with
graft failure and patient death as events. Multivariate
logistic regression analysis was used to identify potential
risk factors for DGF. All tests were two-tailed and P-val-
ues <0.05 were considered as significant. All analyses were
performed using the SPSS statistical software, version 11.0
for PC Windows.
Results
During the 6-year period, there were 59 and 215 renal
transplants from controlled DCD and DBD donors,
respectively. In other words, DCD kidneys made up
21.5% of the DD kidney pool and helped to increase the
Table 2. Recipient characteristics.
Recipient characteristics Mean ± SD or n (%) Range




BMI (kg/m2) 26.8 ± 5.3 15.9–38.2
ESRD etiology







HIV nephropathy 1 (1.7)
Hemolytic uremic syndrome 1 (1.7)
Hepato-renal polycystosis 12 (20.3)
Uropathy 5 (8.5)
Unknown causes 12 (20.3)
Time on waiting list (days) 535.7 ± 498.5 3–2160
Duration of pretransplant
dialysis (days)
933.2 ± 617.1 0–2425*
Residual diuresis (ml) 650.4 ± 748.9 0–2520
Previous transplants
First transplant 55 (93.2)
Re-transplant 4 (6.8)
Peak PRA (%) 11.5 ± 18.7 0–70
PRA at transplant (%) 5.2 ± 15.2 0–75
Number of HLA mismatches
A locus 0.8 ± 0.7 0–2
B locus 1.1 ± 0.4 0–2
DR locus 0.8 ± 0.4 0–2
*One pre-emptive kidney transplant in the context of combined liver-
kidney transplantation.
BMI, body mass index; ESRD, end-stage renal disease; PRA, panel
reactive antibody; HLA, human leukocyte antigens; HIV, human immu-
nodeficiency virus.
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activity of KT up to 27.4% without impairing the DBD
kidney source. The organ procurement and transplanta-
tion activity of the KT program at the University Hospital
of Lie`ge from 2005 to 2010 is presented in Fig. 1.
Functional and survival data
Analysis of Kaplan–Meier survival curves showed overall
and death-censored graft survival rates were 96.6% and
96.6% at 3 months, 94.6% and 96.6% at 1 year, 90.7% and
92.6% at 3 years, and 84.6% and 92.6% at 4 years, respec-
tively (Fig. 2). Five renal grafts were lost during the post-
transplant follow-up, one because of renal vein thrombosis,
one secondary to the relapse of HIV infection in the allo-
graft and three others because of patient deaths. Mean
follow-up of patients was 26.5 months (range: 0.5–
62 months). Patient survival rates at 3 months, 1, 3, and
4 years were 98.3%, 96.3%, 96.3%, and 90.3%, respectively
(Fig. 3). Three patients (5.1%) died during follow-up, one
because of acute myocardial infarction 24 h postoperatively
and other two because of broncho-pneumonitis caused by
CMV and Aspergillus infection at 5 and 41 months.
No PNF grafts were observed in this series. Two recipi-
ents were excluded from the analysis of DGF rates,
because one died 24 h post-transplant and it remain
unknown whether the graft was functioning at the time
of patient death, the other lost the kidney graft because
of renal vein thrombosis. Twenty-six of 57 patients
(45.6%) experienced DGF. The occurrence of DGF did
not adversely influence graft survival, as overall graft sur-
vival rates were 100%, 95%, 95%, and 83.1% for patients
with DGF compared with 100%, 100%, 91.7%, and
91.7% for patients without DGF at 3 months, 1, 3, and
4 years, respectively (P = 0.52, Fig. 4). In addition, DGF
did not increase the risk of acute rejection or surgical
complications: among 26 recipients with DGF, 8 (30.7%)
developed acute rejection compared with 8 (25.8%) recip-
ients without DGF (P = 0.67). The rate of all surgical
complications was 34.6% and 25.8% in recipients with
and without DGF, respectively (P = 0.46).
The use of HMP (n = 10) was associated with a non-
statistically significant lower rate of DGF in comparison
to that of SCS (30% versus 48.5%, respectively, P = 0.31).
Likewise, donor age (‡60 years), donor terminal serum
creatinine (‡15 mg/l), recipient age (‡60 years), recipient
BMI (BMI ‡ 30), kidney allocation policy (national or
international sharing), WIT (‡45 min), suture time
(‡45 min) as well as CIT (‡18 h) had no apparent effect
on the risk for DGF (P = NS, both in univariate and
multivariate logistic regression analysis, Table 3). Donor
body mass index (BMI), in contrast, had an impact on
DGF in multivariate model (not in univariate analysis).
Kidneys from donors with BMI ‡ 30 compared with ones
with BMI < 30 was 17 times more likely to have DGF
(P = 0.03).
One patient was transplanted because of HIV nephrop-
athy and lost quite rapidly her renal allograft (29 months
post-transplant) secondary to the relapse of HIV infection
in the allograft. This was a rare indication of transplanta-
tion and this patient was excluded in the assessment of
renal allograft function. Mean serum creatinine level at
hospital discharge was 22.1 ± 11.7 mg/l (range: 6.8–56.6).
The percentage of patients with serum creatinine level at
hospital discharge <20, 20–40, and >40 mg/l was 61.1%,
25.9%, and 13%, respectively. Renal graft function con-
tinued to improve up to 3 months post-transplant and
nearly stabilized over the following 4 years (Fig. 5). The
mean GFR at hospital discharge, 3 months, 1, and 3 years
was 37.1 ± 16.6, 50.7 ± 11.7, 50.9 ± 11.3, and
49.2 ± 11.2 ml/min, respectively. Among four recipients
who underwent retransplantation, two developed DGF.
However, the four kidney grafts functioned well during
the study period.
Postoperative evolution and complications
The average number of haemodialysis post-transplant in
case of DGF was 4.96 ± 6.01 sessions (range: 1–32). Mean
duration of haemodialysis was 10.6 ± 17.1 days (median:
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Figure 1 Organ donation and kidney transplantation activity in Lie`ge over time. The number of DCD-KT increased without impairing the number
of DBD-KT. DCD: donors after cardiac death. DBD: donors after brain death. KT: kidney transplants.
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(range: 2–32). There was a significant difference in length
of hospitalization between DGF and IGF (immediate graft
function) groups (19.3 ± 5.3 vs. 13.4 ± 3.9 days,
P < 0.001).
Sixteen of 59 patients (27.1%) experienced graft rejec-
tion during the first 3 months post-transplant, making up
17 rejection episodes. Rejection might be either clinically
suspected without graft biopsy (10.1%) or biopsy-proven
at the time of rejection suspicion (8.5%) or diagnosed
only at 3 month protocol biopsy (8.5%).
Early postoperative complications are presented in
Table 4. After hospital discharge, renal artery stenosis was
detected in two patients (3.4%) and stenting was neces-
sary in one of them. Peripheral artery disease developed
in two patients and all of them were stented at the level
of iliac arteries. Infectious complications included pulmo-
nary tuberculosis (one patient) and urinary tract infection
(11 patients). Urologic exploration was performed in one
patient because of repeated urinary infection, but no uri-
nary anomaly was found. Peri-renal lymphocele occurred
in one patient and was treated by puncture aspiration
technique. One patient became pregnant 20 months
post-transplant and gave birth of a healthy boy at 33rd
amenorrheal week because of pre-eclampsia. No urinary
leakage or ureteral obstruction was observed during the
study period.
Discussion
This study showed excellent results of controlled DCD-
KT, which were comparable to those from DBD in the
literature although the use of DCD kidneys led to an ele-
vated rate of DGF because of the unavoidable WIT
between the withdrawal of life-support and the initiation
of cold preservation. DGF increased significantly the
length of hospitalization, nevertheless had no deleterious
impact on post-transplant DCD kidney outcomes as dem-
onstrated in several other studies [19,20]. A recent meta-
analysis in studies with controlled DCD donors showed
no difference in PNF rate between two groups of DBD
Figure 2 Overall and death-censored graft survival after DCD-KT
(n = 59). Overall and actuarial graft survival rates were 96.6% and
96.6% at 3 months, 94.6% and 96.6% at 1 year, 90.7% and 92.6%
at 3 years, and 84.6% and 92.6% at 4 years, respectively.
Figure 3 Overall patient survival after DCD-KT. Patient survival rates
at 3 months, 1, 3, and 4 years were 98.3%, 96.3%, 96.3%, and
90.3%, respectively.
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and DCD kidneys. The only significant difference was the
DGF rate [21]. In our series, we did not experience any
PNF and found a DGF rate of 45.6%. However, this high
rate of DGF was not associated with an increased graft
loss. When evaluating risk factors for DGF, only donor
BMI ‡ 30 was significantly associated with an increased
rate of DGF in multivariate logistic regression model. The
significance of this finding remains unclear.
The DCD kidneys recovered their function slowly and
in majority of cases failed to optimize their function at
the time of hospital discharge. However, their function
continued to improve and nearly normalized at 3 months
post-transplant. Afterward renal allograft function stabi-
lized over the following 4 years. By examining outcomes
of DCD KTs that functioned for at least 1 year and had a
follow-up of 2–5 years, Chapman found that the rate of
graft loss at 5 years was similar between DCD and DBD
Figure 4 Graft and patient survival between DGF and no DGF
groups. The presence of DGF did not adversely influence graft and
patient survival (P = NS).
Table 3. Multivariate logistic regression analysis between the risk of
DGF and different factors linked to the donor, recipient or transplan-
tation procedure.
Factors Odds ratio 95% CI P-value
Donor age ‡50 years 0.902 0.235–3.465 0.881




Recipient age ‡60 years 3.249 0.776–13.610 0.107





WIT ‡30 min 1.982 0.239–16.457 0.527
Suture time ‡45 min 2.276 0.380–23.650 0.368
CIT ‡12 h 2.886 0.572–14.556 0.199
CIT ‡18 h 3.252 0.210–50.358 0.399
Preservation method (HMP) 0.462 0.058–3.647 0.463
DGF, delayed graft function; BMI, body mass index; WIT, warm ische-
mia time; CIT, cold ischemia time; HMP, hypothermic machine perfu-
sion.
Figure 5 Sequential serum creatinine levels over time.
Results of controlled donors after cardio-circulatory death kidney transplantation Ledinh et al.
206 Transplant International ª Michel Meurisse 25 (2012) 201–209
grafts (approximately 3%) and both groups showed simi-
lar declines in GFR after 1 year ()1.3 ml/min for the
DCD group vs. )1.4 ml/min for the DBD group). This
means that DCD kidneys might have a reduced function-
ing glomerular mass because of the initial ischemic dam-
age, but once transplanted there was no evidence of
accelerate deterioration [22].
Graft survival rates in this study were favorably compa-
rable to other reported series [1,4,23,24]. The major cause
of graft loss was patient death with a functioning graft.
Although DCD kidneys experienced worse early trans-
plant outcomes than those coming from DBD donors,
they did provide real survival benefit to patients [25].
Patients who were willing to accept a standard-criteria
DCD kidney had a 56% reduction in mortality risk com-
pared with those remaining on dialysis or awaiting a stan-
dard-criteria DBD kidney. This reduction in mortality
translates into 2.4 months additional expected lifetime
during the first 4 years after transplantation for recipients
of DCD kidneys in comparison with patients who wait
for a DBD kidney [26].
The rate of clinical and subclinical rejection in our
study was similar to that reported in many studies, either
single-center reports [4,27,28], national databases [2,29]
or a recent meta-analysis [21]. DCD kidneys, despite
experiencing greater DGF rates, do not display a greater
incidence of acute allograft rejection episodes (10–19%)
compared with DBD kidneys (9–18%). Similarly, in a
recent publication, Saeb-Parsy did not find any difference
in the rate of major urological complications (urinary
leak and ureteral stenosis) between DCD and DBD kidney
grafts (3.5% versus 1.7%, P = 0.28) [30]. Inversely, Dro-
upy found that the risk of ureteral stenosis and fistula
was significantly higher for DCD than DBD kidneys (15%
vs. 7%, P = 0.04) [31]. In 76 controlled DCD-KT per-
formed at Leiden University Medical Centre, Khairoun
reported one urinary leakage because of ureteral necrosis
and two ureteral obstructions (one after removal of the
double J stent and the other because of blood clot) [32].
The rate of renal artery stenosis in this study was 3.4%.
Although the incidence of transplant renal artery stenosis
is expected to be higher in DCD kidneys because of the
exposure to an excessive ischemic injury, many published
series, as ours, also did not find any significant difference
between DCD and DBD kidneys [33].
Estimates suggested that the potential increase in the
number of DCD kidneys might be 2–4.5 times that of
DBD kidneys [34]. However, in practice, single-center
reports usually described a 20–40% proportion of DCD
KTs among the DD kidney pool [1,24,35,36]. Exception-
ally, a few transplant centers have obtained 50–70%, such
as in Maastricht [37] or Madrid [38,39]. Recently several
transplant centers in the Netherlands [40], the United
Kingdom (UK) [41] and the United States (US) [42] have
observed a remarkable increase in the number of DCD
donors with a concomitant decrease in DBD donors,
resulting in no significant change in the DD pool, some
kind of redistribution of donor types within the pool. We
have not yet observed such a trend in our experience.
No significant difference in the rate of DGF between
ice-stored and machine-perfused DCD kidneys was noted
in this study, although the DGF rate was lower among
machine-perfused grafts. A recent multi-centric random-
ized controlled trial, in which 164 DCD kidney pairs were
split and one allocated to each preservation modality,
convincingly demonstrated that HMP produced less fre-
quent and less severe DGF compared with SCS group
(54% versus 70%) [13]. In a study design similar to Mo-
ers’s study, Watson in the UK found no benefit of HMP
over SCS for DCD kidneys. Nevertheless, the author
emphasized on the ischemia time as an important factor
for the differences between the two trials [43]. A meta-
analysis undertaken by Wright [44] and studies in the US
using the national database [3,45] all confirmed the
advantage of HMP over SCS in DCD kidneys.
Conclusion
The use of controlled DCD kidneys might be an effective
way to increase the number of kidneys available for trans-
plantation because of good transplant outcomes and
Table 4. Early postoperative complications.
Complications n Treatment
Renal vein thrombosis 1 Transplantectomy




Hematuria 5 Bladder irrigation



















2 CPR (1 patient)
Cardiac pace-maker
placement (1 patient)
Anemia 11 Blood transfusion
BPH, benign prostatic hypertrophy; TURP, trans-urethral resection of
prostate; CPR, cardio-pulmonary resuscitation.
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acceptable postoperative complications. Despite a higher
rate of DGF with longer hospitalization, DGF had no
harmful effect on the graft future in this series. By using
this donor source, transplant centers could help optimize
the quality of life and minimize the mortality of end-stage
kidney disease patients on the waiting list.
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